GSK agrees to reduction of H1N1 vaccine doses
London/Munich – Vaccine giant GlaxoSmithKline (GSK) has responded to the demands of the German government to adapt the delivery of Pandremix to Germany’s changing requirements for the H1N1 vaccine. GSK confirmed that it has reached an agreement with the German Ministry of Health to amend its existing contract. The government will now take delivery of approximately 70% of the ordered vaccine, equivalent to 34 million doses. Germany had originally ordered 50 million doses worth EUR416m, but later asked GSK for a reduction of 50% after it became clear that one shot of the jab would provide full protection (more...). The company is currently in discussions with a number of governments regarding their specific pandemic planning requirements (see more...).